ENTEROME

About:

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

Website: http://www.enterome.com

Twitter/X: EnteromeSA

Top Investors: European Investment Bank, Seventure Partners, Takeda, Bristol-Myers Squibb, Omnes Capital

Description:

Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.